Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating.

IF 0.6 4区医学 Q4 ENDOCRINOLOGY & METABOLISM Neuro endocrinology letters Pub Date : 2021-11-30

Anna Babinska, Hanna Olszewska, Krzysztof Sworczak

{"title":"Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating.","authors":"Anna Babinska, Hanna Olszewska, Krzysztof Sworczak","doi":"","DOIUrl":null,"url":null,"abstract":"Context: Pregnancy in acromegaly is rare, there have been few case reports and series published to date. Also breastfeeding under acromegaly treatment is extremely rare. The late diagnosis of pregnancy in acromegaly will sometimes dictate the treatment and management of the patient.Material and method: We present a 32-year-old woman with acromegaly, a late diagnosed pregnancy and a completed fetal organogenesis. Due to the gestation time and bothersome headaches accompanying a pituitary macroadenoma, we decided to continue long lasting somatostatin analogues treatment but with increased injection intervals of 6 weeks. We also continued this treatment during 12 months of breastfeeding.Results: Our treatment did not cause any complication of premature birth or any health problems with the newborn baby. The child has since developed normally up to the age of 5.Conclusion: The course of acromegaly disease and the time of pregnancy diagnosis may prompt suitable drug and treatment regimes. We administered effective and safe somatostatin analogues treatment during gestation and breastfeeding which was safe for both mother and baby.","PeriodicalId":19098,"journal":{"name":"Neuro endocrinology letters","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro endocrinology letters","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Pregnancy in acromegaly is rare, there have been few case reports and series published to date. Also breastfeeding under acromegaly treatment is extremely rare. The late diagnosis of pregnancy in acromegaly will sometimes dictate the treatment and management of the patient.

Material and method: We present a 32-year-old woman with acromegaly, a late diagnosed pregnancy and a completed fetal organogenesis. Due to the gestation time and bothersome headaches accompanying a pituitary macroadenoma, we decided to continue long lasting somatostatin analogues treatment but with increased injection intervals of 6 weeks. We also continued this treatment during 12 months of breastfeeding.

Results: Our treatment did not cause any complication of premature birth or any health problems with the newborn baby. The child has since developed normally up to the age of 5.

Conclusion: The course of acromegaly disease and the time of pregnancy diagnosis may prompt suitable drug and treatment regimes. We administered effective and safe somatostatin analogues treatment during gestation and breastfeeding which was safe for both mother and baby.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

妊娠期和哺乳期肢端肥大症患者生长抑素类似物的安全治疗。

背景:肢端肥大症的妊娠是罕见的，迄今为止只有很少的病例报告和系列出版物。此外，肢端肥大症患者的母乳喂养极为罕见。肢端肥大症中妊娠的晚期诊断有时会决定患者的治疗和管理。材料和方法:我们报告一位32岁的女性肢端肥大症，晚期诊断妊娠，胎儿器官发生完成。由于妊娠时间和伴随垂体大腺瘤的头痛，我们决定继续长期持续的生长抑素类似物治疗，但增加注射间隔为6周。在12个月的母乳喂养期间，我们也继续进行这种治疗。结果:我们的治疗没有引起任何早产并发症或新生儿的任何健康问题。从那以后，这个孩子一直正常发育到5岁。结论:肢端肥大症的病程和妊娠诊断时间可提示合适的药物和治疗方案。我们在妊娠和哺乳期间给予有效和安全的生长抑素类似物治疗，这对母亲和婴儿都是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuro endocrinology letters 医学-内分泌学与代谢

CiteScore

1.00

自引率

14.30%

发文量

审稿时长

6 months

期刊介绍： Neuroendocrinology Letters is an international, peer-reviewed interdisciplinary journal covering the fields of Neuroendocrinology, Neuroscience, Neurophysiology, Neuropsychopharmacology, Psychoneuroimmunology, Reproductive Medicine, Chronobiology, Human Ethology and related fields for RAPID publication of Original Papers, Review Articles, State-of-the-art, Clinical Reports and other contributions from all the fields covered by Neuroendocrinology Letters. Papers from both basic research (methodology, molecular and cellular biology, anatomy, histology, biology, embryology, teratology, normal and pathological physiology, biophysics, pharmacology, pathology and experimental pathology, biochemistry, neurochemistry, enzymology, chronobiology, receptor studies, endocrinology, immunology and neuroimmunology, animal physiology, animal breeding and ethology, human ethology, psychology and others) and from clinical research (neurology, psychiatry and child psychiatry, obstetrics and gynecology, pediatrics, endocrinology, immunology, cardiovascular studies, internal medicine, oncology and others) will be considered. The Journal publishes Original papers and Review Articles. Brief reports, Special Communications, proved they are based on adequate experimental evidence, Clinical Studies, Case Reports, Commentaries, Discussions, Letters to the Editor (correspondence column), Book Reviews, Congress Reports and other categories of articles (philosophy, art, social issues, medical and health policies, biomedical history, etc.) will be taken under consideration.